(Q43680773)

25 November 2017

Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs (English)

1 reference

25 November 2017

1 reference

Burger AJ

1

1 reference

25 November 2017

Charlamb MJ

2

1 reference

25 November 2017

Singh S

3

1 reference

25 November 2017

Notarianni M

4

1 reference

25 November 2017

Blackburn GL

5

1 reference

25 November 2017

Sherman HB

6

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

International Journal of Cardiology

25 November 2017

1 reference

25 November 2017

79

1 reference

25 November 2017

2-3

1 reference

25 November 2017

159-165

1 reference

Valvular heart disease associated with fenfluramine-phentermine

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Long-term weight control study: conclusions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Color Doppler assessment of mitral regurgitation with orthogonal planes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Evaluation of aortic insufficiency by Doppler color flow mapping

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900412-0

7 January 2021

10.1016/S0167-5273(01)00412-0

Identifiers

DOI

1 reference

25 November 2017

1 reference